Balu, Darrick T.

Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction

Balu, D. T., Li, Y., Puhl, M. D., Benneyworth, M. A., Basu, A. C., Takagi, S., Bolshakov, V. Y., & Coyle, J. T. (2013) · Proceedings of the National Academy of Sciences

Schizophrenia research and treatmentAmino Acid Enzymes and Metabolism

Cited by 217

The NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond

Balu, D. T., & Coyle, J. T. (2015) · Current Opinion in Pharmacology

Schizophrenia research and treatmentAmino Acid Enzymes and Metabolism

Cited by 208

Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments

Balu, D. T., Hoshaw, B. A., Malberg, J. E., Rosenzweig-Lipson, S., Schechter, L. E., & Lucki, I. (2008) · Brain Research

Treatment of Major DepressionNerve injury and regeneration

Cited by 194

Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications

Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology

Schizophrenia research and treatmentNeuroscience and Neuropharmacology Research

Cited by 180